TET1 is a Diagnostic and Prognostic Biomarker Associated with Immune Infiltration in Papillary Thyroid Cancer

Overview

Journal Biochem Genet

Specialty Molecular Biology

Date 2023 Jul 6

PMID 37410307

Authors

Yong-Xun Zhao

Li-Bin Ma

Ze Yang

Tao-Hua Zhang

Yong Wang

Cheng Xiang

Affiliations

Soon will be listed here.

Abstract

To investigate the function of ten-eleven translocation 1 (TET1) and its underlying mechanism in papillary thyroid cancer (PTC). Using the RNA-Seq data based on GDC TCGA, we analyzed the gene expression pattern of TET1 in PTC. Immunohistochemistry was carried out to assess the TET1 protein level. Then, its diagnostic and prognostic functions were determined by various bioinformatics approaches. Enrichment analysis was performed to explore the potential pathways in which TET1 is mainly involved. Finally, the immune cell infiltration analysis was conducted and the association of TET1 mRNA expression with the expression levels of immune checkpoints, tumor mutation burden (TMB) score, microsatellite instability (MSI) score, and cancer stem cells (CSC) score was examined. TET1 expression was lower in PTC tissues compared with that in normal tissues (P < 0.01). Besides, TET1 had a certain value in diagnosing PTC, and low-TET1 mRNA expression led to favorable disease-specific survival (DSS) (P < 0.01). The enrichment analysis revealed autoimmune thyroid disease and cytokine-cytokine receptor interaction were the consistent pathways in which TET1 participated. TET1 was negatively correlated with the Stromal score and Immune score. The different proportions of immune cell subtypes were observed between high- and low-TET1 expression groups. Interestingly, TET1 mRNA expression was inversely related to the expression levels of immune checkpoints, and TMB, MSI, and CSC scores. TET1 might be a robust diagnostic and prognostic biomarker for PTC. TET1 affected the DSS of PTC patients possibly through the regulation of immune-related pathways and tumor immunity.

References

Ahn S, Park S, Choi S . Comparison of Consecutive Results from Fine Needle Aspiration and Core Needle Biopsy in Thyroid Nodules. Endocr Pathol. 2017; 28(4):332-338. DOI: 10.1007/s12022-017-9496-1. View

Asadzadeh Z, Safarzadeh E, Safaei S, Baradaran A, Mohammadi A, Hajiasgharzadeh K . Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death. Cancers (Basel). 2020; 12(4). PMC: 7226590. DOI: 10.3390/cancers12041047. View

Bao W, Zi H, Yuan Q, Li L, Deng T . Global burden of thyroid cancer and its attributable risk factors in 204 countries and territories from 1990 to 2019. Thorac Cancer. 2021; 12(18):2494-2503. PMC: 8447914. DOI: 10.1111/1759-7714.14099. View

Chen L, Huang R, Chan M, Yan P, Huang T, Wu R . TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target. J Pathol. 2019; 248(3):363-376. PMC: 6579655. DOI: 10.1002/path.5266. View

Coelho M, Raposo L, Goodfellow B, Atzori L, Jones J, Manadas B . The Potential of Metabolomics in the Diagnosis of Thyroid Cancer. Int J Mol Sci. 2020; 21(15). PMC: 7432278. DOI: 10.3390/ijms21155272. View

da Silva R, Santos J, Uno M, Chammas R, Kulcsar M, SantAnna L . CCNA1 gene as a potential diagnostic marker in papillary thyroid cancer. Acta Histochem. 2020; 122(8):151635. DOI: 10.1016/j.acthis.2020.151635. View

Lopes N, Lens H, Armani A, Marinello P, Cecchini A . Thyroid cancer and thyroid autoimmune disease: A review of molecular aspects and clinical outcomes. Pathol Res Pract. 2020; 216(9):153098. DOI: 10.1016/j.prp.2020.153098. View

Dong W, Horiuchi K, Tokumitsu H, Sakamoto A, Noguchi E, Ueda Y . Time-Varying Pattern of Mortality and Recurrence from Papillary Thyroid Cancer: Lessons from a Long-Term Follow-Up. Thyroid. 2019; 29(6):802-808. DOI: 10.1089/thy.2018.0128. View

Ferrari S, Fallahi P, Galdiero M, Ruffilli I, Elia G, Ragusa F . Immune and Inflammatory Cells in Thyroid Cancer Microenvironment. Int J Mol Sci. 2019; 20(18). PMC: 6769504. DOI: 10.3390/ijms20184413. View

10.

Fu H, Ma Y, Lu L, Hou P, Li B, Jin W . TET1 exerts its tumor suppressor function by interacting with p53-EZH2 pathway in gastric cancer. J Biomed Nanotechnol. 2014; 10(7):1217-30. DOI: 10.1166/jbn.2014.1861. View

11.

Gao R, Ye H, Gao Q, Wang N, Zhou Y, Duan H . Inhibition of circular RNA_0000285 prevents cell proliferation and induces apoptosis in thyroid cancer by sponging microRNA-654-3p. Oncol Lett. 2021; 22(3):673. PMC: 8323011. DOI: 10.3892/ol.2021.12934. View

12.

Good C, Panjarian S, Kelly A, Madzo J, Patel B, Jelinek J . TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer. Cancer Res. 2018; 78(15):4126-4137. PMC: 6072603. DOI: 10.1158/0008-5472.CAN-17-2082. View

13.

Han Q, Zhang X, Ren X, Hang Z, Yin Y, Wang Z . Biological Characteristics and Predictive Model of Biopsy-Proven Acute Rejection (BPAR) After Kidney Transplantation: Evidences of Multi-Omics Analysis. Front Genet. 2022; 13:844709. PMC: 9037533. DOI: 10.3389/fgene.2022.844709. View

14.

Heidari Z, Salimi S, Rokni M, Rezaei M, Khalafi N, Shahroudi M . Association of IL-1, NLRP3, and COX-2 Gene Polymorphisms with Autoimmune Thyroid Disease Risk and Clinical Features in the Iranian Population. Biomed Res Int. 2021; 2021:7729238. PMC: 8592725. DOI: 10.1155/2021/7729238. View

15.

Ito S, DAlessio A, Taranova O, Hong K, Sowers L, Zhang Y . Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 2010; 466(7310):1129-33. PMC: 3491567. DOI: 10.1038/nature09303. View

16.

Jang G, Lee J, Kim Y, Lee S, Han H, Hong K . Interactions between tumor-derived proteins and Toll-like receptors. Exp Mol Med. 2020; 52(12):1926-1935. PMC: 8080774. DOI: 10.1038/s12276-020-00540-4. View

17.

Ji J, You Q, Zhang J, Wang Y, Cheng J, Huang X . Downregulation of TET1 Promotes Glioma Cell Proliferation and Invasion by Targeting Wnt/-Catenin Pathway. Anal Cell Pathol (Amst). 2021; 2021:8980711. PMC: 8677395. DOI: 10.1155/2021/8980711. View

18.

Kao S, Wu K, Lee W . Hypoxia, Epithelial-Mesenchymal Transition, and TET-Mediated Epigenetic Changes. J Clin Med. 2016; 5(2). PMC: 4773780. DOI: 10.3390/jcm5020024. View

19.

Li X, Meng Y . Survival analysis of immune-related lncRNA in low-grade glioma. BMC Cancer. 2019; 19(1):813. PMC: 6697914. DOI: 10.1186/s12885-019-6032-3. View

20.

Li S, Chen X, Liu X, Yu Y, Pan H, Haak R . Complex integrated analysis of lncRNAs-miRNAs-mRNAs in oral squamous cell carcinoma. Oral Oncol. 2017; 73:1-9. DOI: 10.1016/j.oraloncology.2017.07.026. View